Business Daily from THE HINDU group of publications
Wednesday, Feb 14, 2007

Cross Currency

Group Sites

Corporate - Mergers & Acquisitions
Actavis acquires bulk drugs unit of Sanmar Speciality

Our Bureau

Bharat Matrimony

Chennai Feb 13 Actavis, the global pharma major, today announced that it has taken over the bulk drugs division of Chennai-based Sanmar Speciality Chemicals Ltd.

Actavis officials refused to disclose the consideration.

This is Actavis's second acquisition of a Chennai-based company in two months. In December the group had taken over Grandix Pharmaceuticals, a tablets manufacturer.

Mr Robert Wessman, President and CEO of Actavis, told newspersons today that with the acquisition Actavis had captured the entire value chain. He added that Sanmar Speciality would "strongly complement" Actavis's existing manufacturing capabilities in Chennai.

The acquisition gives Actavis 25 active pharmaceutical ingredients (APIs), the term for bulk drug molecules, which Sanmar Speciality had been producing. Actavis intends to produce five more APIs at Sanmar.

In February 2005, Actavis took over Lotus Laboratories in Bangalore, which does bio-equivalence research.

While Lotus does the research, Sanmar would make the bulk drugs and Grandix would produce the tablets, which completes the value chain.

Actavis has so far invested $50-60 million in India, Mr Wessman said, but refused to give an idea of future investments.

He said that the company would raise the capacity of Grandix Pharma from one billion tablets to four billion in two years. Again, no investment details were disclosed.

Actavis also has marketing tie-ups with a number of Indian companies, such as Chennai-based Orchid Chemicals and Shasun Chemicals.

These companies produce formulations, which are marketed in agreed geographies by Actavis.

Asked if more acquisitions in India are in the offing, Mr Wessman said that Actavis had a large M&A division that is always on the lookout for acquisition opportunities.

More Stories on : Mergers & Acquisitions | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bharat Bio to do clinical trials for JE vaccine

Ranbaxy launches generic Lipitor in Denmark
`Converge fully with global financial reporting standards'
Orchid Chem raises $200 m through FCCBs
IVRCL bags Rs 516-cr orders
`India can attract 25% of global engg process outsourcing'
Tax should not be collected without assessment order: HC
Management fest from today
Minda group scouts for acquisitions abroad
`Hindalco, Vodafone deals reflect resilience of economy'
RSM merger to strengthen PwC's focus on combined practices
Lanco Infra, Jindal Steel buy Globeleq interest in Sasan
Actavis acquires bulk drugs unit of Sanmar Speciality
Thomson acquires controlling stake in Paprikaas Animation
NTPC set to award contracts for Simhadri expansion, Ennore plant
Gulf Oil begins mining contract works for Singareni
POSCO land acquisition delayed
The people's choice
Tribal farmers protest against Jindal factory
Tata Motors 2nd trainee batch
`Textile industry not out of the woods fully'
Goel Ganga joins hands with Singapore group for school
IndianOil in talks with Turkey's TAPCO
ONGC plans to drill ultra high-tech wells in onshore assets
Bajaj eyes Rs 10,000-cr turnover
Toyota studying Indian market for Prius roll out
JCB eyes agriculture, mining for growth
DaimlerChrysler plans to drive in CL-class car
HPCL gets new CMD

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line